SHC216V

Sigma-Aldrich

MISSION® TRC2 pLKO.5-puro Non-Target shRNA Control Transduction Particles

Targets no known genes from any species

Synonym(s):
negative shRNA control, shRNA control, negative control, non-target shRNA, MISSION TurboGFP Control Transduction Particles, non-target control, non-target shRNA control
NACRES:
NA.51
Pricing and availability is not currently available.

Quality Level

product line

MISSION®

concentration

≥1x106 VP/ml (via p24 assay)

shipped in

dry ice

storage temp.

−70°C

General description

The MISSION® TRC2 pLKO.5-puro Non-Target shRNA Control Tranduction Particles contain an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION® shRNA library clones. This allows one to examine the effect of transduction of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Transduction Particles are provided as 200 uL at 1 x 106 TU/mL via p24 assay.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit
sigma.com/shrna.

Application

To see more application data, protocols, vector maps visit sigma.com/shrna.

Legal Information

MISSION is a registered trademark of Sigma-Aldrich Co. LLC

RIDADR

UN 3245 9

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.
Pedroza M
Faseb Journal, 30(1), 129-140 (2016)
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
Manier S
Leukemia, 31(4), 853-860 (2017)
Curtis A Clark et al.
Cancer research, 76(23), 6964-6974 (2016-09-28)
PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its...
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
Lewis KM
Lung Cancer, 90(2), 182-190 (2015)
Mesias Pedroza et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(1), 129-140 (2015-09-02)
Lung fibrosis is the hallmark of the interstitial lung diseases. Alveolar epithelial cell (AEC) injury is a key step that contributes to a profibrotic microenvironment. Fibroblasts and myofibroblasts subsequently accumulate and deposit excessive extracellular matrix. In addition to TGF-β, the...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.